Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.

COVID-19 treatments in care homes

The study included almost 30,000 highly vulnerable nursing home residents who were under-represented in previous clinical trials. In addition, more than 26,000 nursing home staff and over 60,000 healthcare workers were studied, with reductions in infections comparable to those seen in nursing home residents.

“This study confirms the great value of the ongoing vaccination programmes to reduce COVID-19 transmission and the related healthcare burden and mortality,” said Dr Carmen Cabezas, Health Secretary for Catalonia. “Our strategy to vaccinate those most at risk first has proven valuable to reduce the impact of COVID-19 on those most likely to suffer severe forms of the disease. In addition, our plan to prioritise those most exposed to the virus, including our healthcare workers, has also proven useful to keep patients and staff safe whilst they care for us.  

Dr Prieto-Alhambra, Professor of Pharmacoepidemiology at Oxford and senior author said: “We are collaborating internationally to produce solid evidence on the risk-benefit of COVID vaccines. Linked real world data from Catalonia and other parts of the world is being used for the study of the safety of vaccines. Here, we used linked primary care, hospital, vaccine, and laboratory data from Catalonia to expand our knowledge on their effectiveness in special subpopulations. The observed effects were in line with those seen in previous clinical trials.”  

The study, published in the British Medical Journal (BMJ), will be useful to understand the benefits of COVID-19 vaccines beyond well-controlled randomised controlled trials, and in populations under-represented in previous studies to date. Preliminary data with a shorter follow-up and study period had been uploaded in a preprint form, and disseminated to the public earlier this year.

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.